Targeted radionuclide therapy for gliomas: Emerging clinical trial landscape
Neuro-Oncology · 09.12.2024 · 26 (Supplement_9) · S208-S214
DOI: 10.1093/neuonc/noae125 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neuro-Oncology, online erschienen am 06.08.2024. Verfasst von Michael Weller und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Glioma, Brain Neoplasms, Radiopharmaceuticals. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
According to the new WHO classification of 2021, gliomas are a heterogeneous group of tumors with very different histology, molecular genetics, and prognoses. In addition to glioblastomas, the most common gliomas, there are also numerous less common gliomas, some of which have a very favorable prognosis. Targeted radionuclide therapy is a therapeutic option that can be attractive if a tumor can be targeted based on its molecular characteristics. It is particularly useful when tumors cannot be completely resected or when conventional imaging does not fully capture the extent of the tumor. Numerous approaches to radionuclide therapy for gliomas are in early development. The most advanced approaches for patients with gliomas in the clinic employ L-type amino acid transporter 1 as an uptake mechanism for radiolabeled amino acids or target somatostatin receptor 2 or gastrin-releasing peptide receptor. Here, we discuss the various target structures of radionuclide therapy in gliomas and provide an outlook for which glioma entities radionuclide therapy could most likely provide a therapeutic alternative.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
- Department of Nuclear Medicine, LMU Hospital, LMU Munich, Munich, Germany.
- Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
- Institute of Neuroscience and Medicine (IMN-3), Research Center Juelich, Juelich, Germany.
- Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Cologne, Germany.
- Department of Neuroradiology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
ORCID-Profile: Michael Weller, Nathalie L Albert, Norbert Galldiks, Andrea Bink, Matthias Preusser, Erik P Sulman, Valerie Treyer, Patrick Y Wen, Joerg C Tonn, Emilie Le Rhun
Zitieren
APA
Weller, M., Albert, N. L., Galldiks, N., Bink, A., Preusser, M., Sulman, E. P., Treyer, V., Wen, P. Y., Tonn, J. C., & Le Rhun, E. (2024). Targeted radionuclide therapy for gliomas: Emerging clinical trial landscape. Neuro-Oncology, 26(Supplement_9), S208-S214. https://doi.org/10.1093/neuonc/noae125
Vancouver
Weller M, Albert NL, Galldiks N, Bink A, Preusser M, Sulman EP, et al. Targeted radionuclide therapy for gliomas: Emerging clinical trial landscape. Neuro-Oncology. 2024;26(Supplement_9):S208-S214. doi:10.1093/neuonc/noae125
BibTeX
@article{Weller2024,
author = {Weller, Michael and Albert, Nathalie L and Galldiks, Norbert and Bink, Andrea and Preusser, Matthias and Sulman, Erik P and Treyer, Valerie and Wen, Patrick Y and Tonn, Joerg C and Le Rhun, Emilie},
title = {Targeted radionuclide therapy for gliomas: Emerging clinical trial landscape},
journal = {Neuro-Oncology},
year = {2024},
volume = {26},
number = {Supplement_9},
pages = {S208--S214},
doi = {10.1093/neuonc/noae125}
}
EUVIMED